Woodard & Company Asset Management Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$218K Sell
866
-7,398
-90% -$1.59M 0.03% 115
2026
Q1
$1.8M Sell
8,264
-76
-0.9% -$16.9K 0.29% 52
2025
Q4
$1.91M Buy
8,340
+166
+2% +$37.8K 0.3% 51
2025
Q3
$1.89M Hold
8,174
0.31% 48
2025
Q2
$1.52M Sell
8,174
-100
-1% -$18.6K 0.28% 51
2025
Q1
$1.73M Hold
8,274
0.36% 40
2024
Q4
$1.47M Hold
8,274
0.32% 46
2024
Q3
$1.63M Buy
8,274
+34
+0.4% +$6.35K 0.37% 42
2024
Q2
$1.41M Sell
8,240
-200
-2% -$33.1K 0.35% 42
2024
Q1
$1.54M Sell
8,440
-100
-1% -$17.2K 0.41% 38
2023
Q4
$1.32M Hold
8,540
0.39% 38
2023
Q3
$1.27M Sell
8,540
-118
-1% -$17.3K 0.43% 37
2023
Q2
$1.17M Buy
8,658
+118
+1% +$17.3K 0.39% 42
2023
Q1
$1.36M Sell
8,540
-60
-0.7% -$9.17K 0.47% 37
2022
Q4
$1.39M Buy
8,600
+160
+2% +$24.5K 0.49% 33
2022
Q3
$1.13M Hold
8,440
0.52% 32
2022
Q2
$1.29M Sell
8,440
-315
-4% -$48.1K 0.53% 30
2022
Q1
$1.42M Sell
8,755
-200
-2% -$29.1K 0.59% 31
2021
Q4
$1.21M Buy
8,955
+175
+2% +$20.7K 0.58% 26
2021
Q3
$947K Hold
8,780
0.58% 30
2021
Q2
$989K Hold
8,780
0.59% 30
2021
Q1
$950K Hold
8,780
0.6% 32
2020
Q4
$941K Hold
8,780
0.58% 29
2020
Q3
$769K Buy
8,780
+40
+0.5% +$3.77K 0.5% 29
2020
Q2
$858K Buy
8,740
+300
+4% +$26.4K 0.58% 30
2020
Q1
$643K Buy
8,440
+110
+1% +$9.37K 0.46% 31
2019
Q4
$738K Buy
8,330
+90
+1% +$7.47K 0.44% 33
2019
Q3
$624K Buy
8,240
+700
+9% +$48K 0.4% 37
2019
Q2
$548K Hold
7,540
4.23% 4
2019
Q1
$608K Hold
7,540
5.11% 3
2018
Q4
$695K Sell
7,540
-700
-8% -$61.6K 7.03% 3
2018
Q3
$779K Hold
8,240
0.71% 18
2018
Q2
$763K Hold
8,240
0.74% 17
2018
Q1
$780K Hold
8,240
0.76% 17
2017
Q4
$797K Buy
+8,240
New +$777K 0.69% 16

Other funds holding ABBV

Woodard & Company Asset Management Group's ABBV Position: Q2 2026 in Review

Woodard & Company Asset Management Group reduced its AbbVie (ABBV) stake by 90% in Q2 2026, selling an estimated $1.59M and leaving 866 shares worth $218K. The position accounts for 0.03% of the portfolio, ranked #115.

Woodard & Company Asset Management Group first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.91M in Q4 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Woodard & Company Asset Management Group held 866 shares of AbbVie worth $218K as of Q2 2026.
  • Woodard & Company Asset Management Group sold 7,398 AbbVie shares in Q2 2026, an estimated $1.59M.
  • AbbVie made up 0.03% of Woodard & Company Asset Management Group's portfolio in Q2 2026, its #115 holding.
  • Woodard & Company Asset Management Group first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
  • Woodard & Company Asset Management Group's AbbVie position peaked at $1.91M in Q4 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Woodard & Company Asset Management Group's 13F filing for Q2 2026, filed 29 Jul 2026.